Zevra Therapeutics Balance Sheet
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zevra Therapeutics financial position
At the end of fiscal 2025, Zevra Therapeutics reported total assets of $284.7 million, up 59.8% from a year earlier against total liabilities of $130.1 million. Shareholders' equity stood at $154.7 million, or 54.3% of assets. The company held $62.4 million in cash and equivalents against $61.9 million of debt, a net cash position of $478,000.
The current ratio (current assets divided by current liabilities) was 5.68, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.40.
Summary generated from market data by MetaCap's automated system. Methodology
Zevra Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 62.41M | 33.78M | 43.05M | 65.47M | 112.35M | 4.21M | 3.22M | 18.41M | 10.87M | 16.76M |
| Short-Term Investments | 128.60M | 35.71M | 24.69M | 16.90M | 0 | — | — | 3.26M | 31.36M | 51.00M |
| Receivables | — | 10.18M | 16.12M | 7.18M | 1.42M | 2.44M | 1.68M | 0 | 2.00M | 5.00M |
| Inventory | 1.74M | 1.97M | 0 | 671.00K | — | — | — | — | — | — |
| Total Current Assets | 223.01M | 86.03M | 86.94M | 92.83M | 115.06M | 8.38M | 6.97M | 23.72M | 45.90M | 74.36M |
| Property, Plant & Equipment | 489.00K | 356.00K | 736.00K | 794.00K | 884.00K | 1.04M | 1.47M | 1.75M | 2.00M | 1.97M |
| Goodwill | 4.70M | 4.70M | 4.70M | 0 | — | — | — | — | — | — |
| Intangible Assets | 6.42M | 68.99M | 69.23M | 0 | — | — | — | — | — | — |
| Long-Term Investments | 47.88M | 6.01M | 0 | 0 | 15.42M | 0 | — | — | 3.25M | 8.20M |
| Total Assets | 284.73M | 178.13M | 172.33M | 115.34M | 132.94M | 11.21M | 10.51M | 26.75M | 52.46M | 84.89M |
| Accounts Payable | 2.48M | 13.07M | 13.99M | 3.61M | 516.00K | 1.17M | 1.14M | 3.71M | 2.18M | 469.00K |
| Total Current Liabilities | 39.28M | 34.06M | 73.72M | 12.02M | 4.23M | 7.54M | 5.43M | 12.00M | 11.51M | 6.64M |
| Long-Term Debt | 61.93M | 59.50M | 5.07M | 0 | — | 67.66M | 77.34M | 81.44M | 92.73M | — |
| Total Liabilities | 130.07M | 138.46M | 110.46M | 40.22M | 5.82M | 77.62M | 84.96M | 93.31M | 109.97M | 103.58M |
| Shareholders' Equity | 154.66M | 39.67M | 61.86M | 75.12M | 101.66M | -66.41M | -74.46M | -66.57M | -57.52M | -18.70M |
| Retained Earnings | -422.06M | -505.29M | -399.78M | -353.73M | -267.03M | -258.47M | -245.71M | -221.19M | -164.73M | -121.34M |
| Total Debt | 61.93M | 59.50M | 5.07M | 0 | — | 67.66M | 77.34M | 81.44M | 92.73M | — |
| Net Cash (Debt) | 129.08M | 9.99M | 62.67M | 82.37M | 112.35M | -63.45M | -74.13M | -59.77M | -50.50M | 67.77M |
| Shares Outstanding | 56.85M | 53.67M | 41.53M | 34.54M | 35.01M | 4.54M | 2.27M | 1.65M | 14.66M | 14.65M |
This table shows 10 annual periods of Zevra Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ZVRA's reporting calendar. What is a balance sheet?